Jeanna Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jeanna Kim has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Abdullah H. Feroze
Department of Neurological Surgery, University of Washington, Seattle, USA
1 shared publication Adrian Begaye
Stanford University School of Medicine, Stanford, CA 94305, USA
1 shared publicationAlexander Barrett
Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
1 shared publication- Allen B. Tu
VA Palo Alto Health Care System, Palo Alto, California, USA
1 shared publication Andrea R. Lim
Public Health Sciences Division/Translational Research Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
1 shared publicationArko Dasgupta
Public Health Sciences Division/Translational Research Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
1 shared publication
Latest Publications
- 21 January 2019
- Published by Springer Nature in Nature Cell Biology
- Vol. 21 (2) , 238-250
Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy
The presence of disseminated tumour cells (DTCs) in bone marrow is predictive of poor metastasis-free survival of patients with breast cancer with localized disease. DTCs persist in distant tissues despite systemic administration of adjuvant chemotherapy. Many assume that this is because the majority of DTCs are quiescent. Here, we challenge this notion and provide evidence that the microenvironment of DTCs protects them from chemotherapy, independent of cell cycle status. We show that chemoresistant DTCs occupy the perivascular niche (PVN) of distant tissues, where they are protected from therapy by vascular endothelium. Inhibiting integrin-mediated interactions between DTCs and the PVN, driven partly by endothelial-derived von Willebrand factor and vascular cell adhesion molecule 1, sensitizes DTCs to chemotherapy. Importantly, chemosensitization is achieved without inducing DTC proliferation or exacerbating chemotherapy-associated toxicities, and ultimately results in prevention of bone metastasis. This suggests that prefacing adjuvant therapy with integrin inhibitors is a viable clinical strategy to eradicate DTCs and prevent metastasis.
- 21 January 2019
- Published by Springer Nature in Nature Cell Biology
- Vol. 21 (2) , 238-250
Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy
The presence of disseminated tumour cells (DTCs) in bone marrow is predictive of poor metastasis-free survival of patients with breast cancer with localized disease. DTCs persist in distant tissues despite systemic administration of adjuvant chemotherapy. Many assume that this is because the majority of DTCs are quiescent. Here, we challenge this notion and provide evidence that the microenvironment of DTCs protects them from chemotherapy, independent of cell cycle status. We show that chemoresistant DTCs occupy the perivascular niche (PVN) of distant tissues, where they are protected from therapy by vascular endothelium. Inhibiting integrin-mediated interactions between DTCs and the PVN, driven partly by endothelial-derived von Willebrand factor and vascular cell adhesion molecule 1, sensitizes DTCs to chemotherapy. Importantly, chemosensitization is achieved without inducing DTC proliferation or exacerbating chemotherapy-associated toxicities, and ultimately results in prevention of bone metastasis. This suggests that prefacing adjuvant therapy with integrin inhibitors is a viable clinical strategy to eradicate DTCs and prevent metastasis.
- 10 May 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (389)
Leukotriene B4antagonism ameliorates experimental lymphedema
Lymphedema is a common debilitating condition with very limited treatment options, and leukotriene B4may be a key pathogenic molecule and therapeutic target.
- 10 May 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (389)
Leukotriene B4antagonism ameliorates experimental lymphedema
Lymphedema is a common debilitating condition with very limited treatment options, and leukotriene B4may be a key pathogenic molecule and therapeutic target.